| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Diadexus, Inc. |
| 3303 Octavius Drive, Santa Clara, CA 95054 * (408) 496-6600 |
| Business Description | The company is a post-genomics company focused on translating raw genomics data into novel diagnostic and therapeutic products. |
|
Filing Information Not yet | |||
| To Trade As | DDXS (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 11/20/00 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $100,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Lehman Brothers Incorporated | Lead Manager | (212) 526-8100 |
| CIBC World Markets | Co-manager | (212) 667-7400 |
| Fidelity Capital Markets | Co-manager | |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | 9/30/99 | 9/30/00 | ||
| Revenues | - | - | 0.000 | 0.000 | 0.100 | 0.100 | 0.000 |
| Income from Oper. | - | - | -0.680 | -8.643 | -11.706 | -9.431 | -11.085 |
| Net Income | - | - | -0.548 | -7.928 | -11.286 | -8.916 | -7.799 |
| E.P.S | - | - | - | - | -1.280 | - | -0.450 |
| Revenue Growth (%) | - | - | - | - | -100.00 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -12.87 | -9.31 | -4.15 | ||||
| Cash Flow - Inv. | -0.23 | -0.19 | -63.11 | ||||
| Cash Flow - Fin. | 5.00 | 5.00 | 90.14 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/00 | Financial Ratios | ||||
| Total Assets | 97.46 | Current Assets | 71.80 | Current Ratio | 41.81 |
| Total Liab. | 1.77 | Current Liab. | 1.72 | Debt Ratio | 1.82% |
| Total Equity | 95.69 | Working Cap. | 70.08 | Debt to Equity Ratio | 0.02 |
| Cash | 31.24 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to expand discovery, validation and product development capabilities for diagnostic and therapeutic product candidates and for general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Latham & Watkins |
| Bank's Law Firm | Mintz & Gold, LLP |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| SmithKline Beecham Corporation | 49.60 | |
| Incyte Genomics, Inc. | 19.80 | |
| American Express affiliated entities | 10.70 | |
| Bank of America Venture Partners affiliated entities | 7.00 | |
| Moore Global Investments affiliated entities | 6.40 | |
| Note: represents ownership of 5% or more prior to the offering. | ||